UK leaders: Takeda’s Jon NealIn the first of a new series where we talk to GMs of UK pharma divisions, managing director Share XUK leaders: Takeda’s Jon Nealhttps://pharmaphorum.com/views-analysis-market-access/uk-leaders-takeda-jon-neal/
Q&A: Fortress Biotech’s Lindsay Rosenwald on breathing new life into sidelined drugsOne downside of the explosion in our knowledge about potential drug targets is that many promising candidates are Share XQ&A: Fortress Biotech’s Lindsay Rosenwald on breathing new life into sidelined drugshttps://pharmaphorum.com/views-analysis-market-access/qa-fortress-biotech-on-breathing-new-life-into-sidelined-drugs/
3 key trends shaping the immunology marketFrom an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an Share X3 key trends shaping the immunology markethttps://pharmaphorum.com/views-analysis-market-access/3-key-trends-shaping-the-immunology-market/
Bridging the gap between global trials and regional processesRegional differences in processes and regulations are compounding the challenges of 21st century clinical trial management. Is greater Share XBridging the gap between global trials and regional processeshttps://pharmaphorum.com/r-d/views-analysis-r-d/bridging-the-gap-between-global-trials-and-regional-processes/
Has pharma been too slow to respond to coronavirus?The new coronavirus strain emerging in China is making headlines across the world, with the disease sending entire Share XHas pharma been too slow to respond to coronavirus?https://pharmaphorum.com/r-d/views-analysis-r-d/has-pharma-been-too-slow-to-respond-to-coronavirus/
“Fake news” and credibility in medical publishingNatalie Yeadon looks at how the industry can help healthcare professionals, patients, and their families combat false and Share X“Fake news” and credibility in medical publishinghttps://pharmaphorum.com/r-d/views-analysis-r-d/fake-news-and-credibility-in-medical-publishing/
Antibody-drug conjugates on the marchOne of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal Share XAntibody-drug conjugates on the marchhttps://pharmaphorum.com/views-analysis-oncology/antibody-drug-conjugates-on-the-march/
Information hubs and the beginning of a data-driven futureWill 2020 be the year the UK harnesses the potential of its health data, as seven new national Share XInformation hubs and the beginning of a data-driven futurehttps://pharmaphorum.com/r-d/views-analysis-r-d/information-hubs-and-the-beginning-of-a-data-driven-future/
How cell and gene therapies are transforming pharma deal-makingAfter decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to Share XHow cell and gene therapies are transforming pharma deal-makinghttps://pharmaphorum.com/r-d/views-analysis-r-d/how-cell-and-gene-therapies-are-transforming-pharma-deal-making/
